Mologen offers lefitolimod rights to iPharma; definitive agreement not reached
Mologen AG and iPharma Ltd. signed a binding term sheet that could culminate with iPharma gaining exclusive rights to develop and sell Mologen’s Phase III oncology project lefitolimod (MGN1703) in China, Hong Kong, Macau, Taiwan, and Singapore.
- Large Molecule
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com